Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CHMP on NSAIDs

This article was originally published in The Tan Sheet

Executive Summary

EMEA's Committee on Human Medicinal Products met Sept. 12-15 to review the link between NSAIDs and adverse events such as GI bleeding and skin rashes, yet does not expect to reach a conclusion until October. The committee "continued its assessment of the available data on the cardiovascular, gastro-intestinal and skin safety of non-selective non-steroidal anti-inflammatory drugs," the European Medicine Agency announces in a release Sept. 15. "It is expected that an overall view on the different safety aspects considered in this review will be reached during the Committee's October 2005 meeting." In August, the Committee announced that it did not recommend any changes to labeling information or advice given to patients and physicians about NSAID use (1"The Tan Sheet" Aug. 8, 2005, p. 6)...
Advertisement

Related Content

European Health Agency NSAID Review Recommends No Changes
European Health Agency NSAID Review Recommends No Changes

Topics

Advertisement
UsernamePublicRestriction

Register

PS098645

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel